Integra LifeSciences price target lowered to $15 from $19 at Truist

Truist lowered the firm’s price target on Integra LifeSciences (IART) to $15 from $19 and keeps a Hold rating on the shares. The firm notes the company reported a Q1 revenue beat, but overshadowing was a light EPS and lower FY25 organic growth/EPS gdce, including $22M tariff impact, $28M-$43M of incremental FY25 ship hold impact, and a lower Private Label rev. expectation. Truist also points out that Q2 guidance was below CNS, largely because of a newly identified ship hold. The firm stays on the sidelines pending greater confidence share recapture in impacted markets has not been structurally damaged from extended ship holds and that compliance issues plus estimates reductions are in rear view.